Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2019 | 12-2018 | 06-2018 | 12-2017 | 09-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,403,080 | 2,651,070 | 2,129,616 | 3,918,252 | 3,878,055 |
| Marketable Securities | 194,212 | 13,940,340 | 176,152 | 233,420 | 267,939 |
| Receivables | 7,176,524 | 4,590,540 | 4,229,378 | 4,616,296 | 4,237,713 |
| Inventories | 8,212,950 | 1,988,242 | 2,037,101 | 2,003,399 | 2,108,700 |
| Other current assets | 5,695,854 | 593,448 | 1,028,395 | 495,833 | 505,553 |
| TOTAL | $26,682,620 | $23,763,640 | $9,600,642 | $11,267,200 | $10,997,960 |
| Non-Current Assets | |||||
| PPE Net | 13,478,130 | 5,355,789 | 4,859,026 | 4,821,023 | 4,870,881 |
| Investments And Advances | 2,811,327 | 2,517,409 | 3,045,835 | 2,865,177 | 2,848,770 |
| Intangibles | 78,668,710 | 18,456,126 | 19,430,243 | 19,150,175 | 19,490,391 |
| Other Non-Current Assets | 1,668,063 | 1,235,316 | 1,332,356 | 1,150,395 | 1,175,578 |
| TOTAL | $96,626,230 | $27,564,640 | $28,667,460 | $27,986,770 | $28,385,620 |
| Total Assets | $123,308,900 | $51,328,290 | $38,268,110 | $39,253,960 | $39,383,590 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 4,738,051 | 1,074,613 | 10,902 | 1,246,000 | 1,259,901 |
| Accounts payable and accrued liabilities | 2,537,863 | 2,212,682 | 2,074,526 | 1,988,723 | 1,887,093 |
| Other current liabilities | 10,129,360 | 3,932,928 | 4,084,984 | 3,719,390 | 3,593,835 |
| TOTAL | $18,260,270 | $7,758,192 | $6,747,685 | $7,815,713 | $7,548,921 |
| Non-Current Liabilities | |||||
| Long Term Debt | 46,701,050 | 21,609,560 | 9,142,831 | 8,886,356 | 8,976,321 |
| Other Non-Current Liabilities | 6,621,288 | 2,840,130 | 2,433,305 | 2,522,042 | 2,516,444 |
| TOTAL | $60,691,090 | $25,391,150 | $12,507,940 | $12,444,910 | $12,883,400 |
| Total Liabilities | $78,951,350 | $33,149,340 | $19,255,630 | $20,260,620 | $20,432,320 |
| Shareholders' Equity | |||||
| Common Shares | 15,179,640 | 693,684 | 716,892 | 589,474 | 593,613 |
| Retained earnings | 12,785,740 | 14,372,650 | 14,658,330 | 14,327,580 | 14,529,290 |
| Other shareholders' equity | 2,076,360 | 2,846,434 | 3,457,762 | 3,869,265 | 3,666,498 |
| TOTAL | $44,357,500 | $18,178,940 | $19,012,480 | $18,993,350 | $18,951,270 |
| Total Liabilities And Equity | $123,308,850 | $51,328,280 | $38,268,110 | $39,253,970 | $39,383,590 |